CD8A and neoplasm: Paboxicillin and Ribociclib (61), inhibitors of CDK4/6 combined with PD-L1 antibody enhance the ability of CD8+ T cells to secrete IFN-γ (interferon-γ), promote T cell-mediated anti-tumor immune response and significantly increase survival (61).